1.16
+0.04(+3.57%)
Currency In USD
| Previous Close | 1.12 |
| Open | 1.12 |
| Day High | 1.21 |
| Day Low | 1.12 |
| 52-Week High | 3.94 |
| 52-Week Low | 0.88 |
| Volume | 4.72M |
| Average Volume | 5.19M |
| Market Cap | 165.67M |
| PE | -4.3 |
| EPS | -0.27 |
| Moving Average 50 Days | 1.08 |
| Moving Average 200 Days | 1.68 |
| Change | 0.04 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $119.96 as of February 26, 2026 at a share price of $1.16. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 5 years ago, it would be worth $100 as of February 26, 2026 at a share price of $1.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked struc
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient